Susquehanna options strategist Alison Edwards notes call buying activity in Celgene (NASDAQ: CELG), as an investor bought 3k Mar 110 Calls for $2.85, adding to Feb call buying yesterday, following CELG's reported acquisition of Juno Therapeutics (NASDAQ: JUNO) for $87 per share.